Publications by authors named "F Krackhardt"
Background: Gender-specific outcomes after percutaneous coronary interventions were studied by a number of research groups with different endpoints and cohorts of different ethnic extractions. The purpose of this report is to use propensity score matching to determine gender-specific differences in clinical outcomes after percutaneous coronary interventions with polymer-free sirolimus-coated stents.
Materials And Methods: The basis for this post hoc analysis was two large all-comers studies with prospectively enrolled patients from Europe and Asia.
Article Synopsis
- - The study investigates whether using the novel sirolimus eluting balloon (SEB) along with provisional drug-eluting stents (DES) is as effective as using DES alone in preventing target vessel failure (TVF) after percutaneous coronary intervention (PCI) over a 5-year period.
- - It is a multi-center, randomized trial that will enroll 3,326 patients across 50 sites in Europe and Asia, focusing on those with specific coronary conditions, while excluding certain high-risk cases.
- - The trial will evaluate TVF rates and various outcomes, including bleeding events and cost-effectiveness, at multiple follow-up points, aiming to determine if the SEB strategy is at least as good as, or possibly
Background: In most cases of transcatheter valve embolization and migration (TVEM), the embolized valve remains in the aorta after implantation of a second valve into the aortic root. There is little data on potential late complications such as valve thrombosis or aortic wall alterations by embolized valves.
Aims: The aim of this study was to analyze the incidence of TVEM in a large cohort of patients undergoing transcatheter aortic valve implantation (TAVI) and to examine embolized valves by computed tomography (CT) late after TAVI.
Purpose: This study evaluated whether patient support, administered via an electronic device-based app, increased adherence to treatment and lifestyle changes in patients with acute coronary syndrome (ACS) treated with ticagrelor in routine clinical practice.
Methods: Patients (aged ≥ 18 years) with diagnosed ACS treated with ticagrelor co-administered with low-dose acetylsalicylic acid were randomized into an active group (with support tool app for medication intake reminders and motivational messages) and a control group (without support tool app), and observed for 48 weeks (ClinicalTrials.gov Identifier: NCT02615704).